<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209221</url>
  </required_header>
  <id_info>
    <org_study_id>NP25342</org_study_id>
    <nct_id>NCT01209221</nct_id>
  </id_info>
  <brief_title>A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Placebo-controlled, Randomized, Observer-blind Combined Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5271983 in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This placebo-controlled, randomized, observer-blind, dose-ascending study will investigate
      the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses
      of RO5271983 in healthy volunteers. Healthy volunteers will be randomized to receive either a
      single oral dose of RO5271983 or placebo in the SAD part or multiple oral doses of RO5271983
      or placebo in the MAD part. The anticipated time on study treatment is approximately 14 weeks
      for the SAD part and up to 8 weeks for the MAD part.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single ascending dose (SAD): Pharmacokinetics (plasma concentration) of RO5271983</measure>
    <time_frame>up to 240 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single ascending dose (SAD): Safety (incidence of adverse events)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single ascending dose (SAD): Tolerability (e.g. vital signs)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple ascending doses (MAD): Pharmacokinetics (plasma concentration) of RO5271983</measure>
    <time_frame>17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple ascending doses (MAD): Safety (incidence of adverse events)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple ascending doses (MAD): Tolerability (e.g. vital signs)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of food on pharmacokinetics of RO5271983</measure>
    <time_frame>up to 240 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single ascending dose (SAD): Pharmacodynamics (blood analysis) of RO5271983</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple ascending doses (MAD): Pharmacodynamics (blood analysis) of RO5271983</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - MAD</intervention_name>
    <description>Once or twice daily doses of matching placebo to RO5271983 for 14 days</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - SAD</intervention_name>
    <description>Single dose of matching placebo to RO5271983 for up to 3 periods</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5271983 - MAD</intervention_name>
    <description>Once or twice daily doses of RO5271983 for 14 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5271983 - SAD</intervention_name>
    <description>Single dose of RO5271983 at each period (for up to 3 periods)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers, 18-65 years of age

          -  Body Mass Index (BMI) between 18 and 32 kg/m2, inclusive

          -  In the SAD, females subjects must be surgically sterile or post-menopausal for the
             past year; in the MAD females may be of child-bearing potential but must use 2 methods
             of highly effective contraception

        Exclusion Criteria:

          -  A history of clinically relevant cardiovascular, gastrointestinal, hepatic, renal,
             endocrine, pulmonary, neurological, psychiatric, allergic or skin disease

          -  Clinical significant abnormalities in laboratory test results

          -  Symptoms of an infectious disease including upper respiratory tract infection within
             one month of study start or a history of recurrent infections

          -  Smokers of &gt;5 cigarettes/day within 3 months prior to admission and unable to stop
             smoking during study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

